Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-08-25 00:00:00 ET · period of report 2023-08-23 · accession 0001968202-23-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-25 | 2023-08-23 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $399.66 | +7,000 | 26.1K | +37% | +$2.80M |
| D | 2023-08-25 | 2023-08-23 | REGN | Fenimore Christopher R. | SVP Ctrl | F - Tax | $842.66 | -5,198 | 20.9K | -20% | -$4.38M |
| D | 2023-08-25 | 2023-08-23 | REGN | Fenimore Christopher R. | SVP Ctrl | M - OptEx | $0.00 | -7,000 | 10.0K | -41% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-23 | M | A | 7,000 | $399.66 | 26,140 | D | — | — | |
| 2 | Common | Common Stock | 2023-08-23 | F | D | 5,198 | $842.66 | 20,942 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-08-23 | M | D | 7,000 | $0.00 | 10,000 | D | $399.66 · — to 2024-12-16 | 7,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |